Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

Adma Biologics Inc (NASDAQ: ADMA) closed the day trading at $17.2 up 0.88% from the previous closing price of $17.05. In other words, the price has increased by $0.88 from its previous closing price. On the day, 3.84 million shares were traded. ADMA stock price reached its highest trading level at $17.34 during the session, while it also had its lowest trading level at $16.815.

Ratios:

For a better understanding of ADMA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 57.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 45.30. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 6.58. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.

On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.

Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 15 ’25 when Grossman Adam S sold 21,000 shares for $18.66 per share. The transaction valued at 391,860 led to the insider holds 2,037,850 shares of the business.

Grossman Adam S bought 63,000 shares of ADMA for $1,176,840 on Jul 15 ’25. On Jun 16 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $20.81 each. As a result, the insider received 437,010 and left with 2,043,850 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4106224896 and an Enterprise Value of 4116616960. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.38, and their Forward P/E ratio for the next fiscal year is 18.36. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.94 while its Price-to-Book (P/B) ratio in mrq is 10.99. Its current Enterprise Value per Revenue stands at 8.961 whereas that against EBITDA is 25.738.

Stock Price History:

The Beta on a monthly basis for ADMA is 0.38, which has changed by 0.31498468 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $10.21. The 50-Day Moving Average of the stock is -9.99%, while the 200-Day Moving Average is calculated to be -8.32%.

Shares Statistics:

Over the past 3-months, ADMA traded about 3.24M shares per day on average, while over the past 10 days, ADMA traded about 2535190 shares per day. A total of 238.53M shares are outstanding, with a floating share count of 230.53M. Insiders hold about 3.43% of the company’s shares, while institutions hold 86.56% stake in the company. Shares short for ADMA as of 1751241600 were 16238070 with a Short Ratio of 5.02, compared to 1748563200 on 14312460. Therefore, it implies a Short% of Shares Outstanding of 16238070 and a Short% of Float of 8.3500005.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Earnings Estimates

Investors are keenly observing as 2.0 analysts analyze and rate the current performance of Adma Biologics Inc (ADMA) in the stock market.The consensus estimate for the next quarter is $0.17, with high estimates of $0.17 and low estimates of $0.17.

Analysts are recommending an EPS of between $0.61 and $0.6 for the fiscal current year, implying an average EPS of $0.61. EPS for the following year is $0.96, with 2.0 analysts recommending between $0.97 and $0.95.

Revenue Estimates

3 analysts predict $121.77M in revenue for the current quarter. It ranges from a high estimate of $123M to a low estimate of $121.1M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $107.19MFor the next quarter, 3 analysts are estimating revenue of $130.3M. There is a high estimate of $133.3M for the next quarter, whereas the lowest estimate is $126.9M.

A total of 3 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $505.8M, while the lowest revenue estimate was $502.7M, resulting in an average revenue estimate of $504.57M. In the same quarter a year ago, actual revenue was $426.45MBased on 4 analysts’ estimates, the company’s revenue will be $633.16M in the next fiscal year. The high estimate is $641.2M and the low estimate is $629.4M.